Author(s)
Guerrero ML1, Jamotte A2, Tamayo R3, Hernandez A4, Galindo-Fraga A1, Ortiz AA5, Cervantes P3, Lopez JG3, Beigel JH6, Ruiz-Palacios GM7
1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Ciudad de Mexico, Mexico, 2Creativ-Ceutical, Paris, France, 3Sanofi, Mexico City, Mexico, 4Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 5Instituto Nacional de Pediatría, Mexico City, Mexico, 6Leidos Biomedical Research, Inc, support to National Institute of Allergy and Infectious Diseases, Frederick, Maryland, MD, USA, 7Comision Coordinadora de los Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud, Mexico, Mexico City, Mexico
OBJECTIVES: To estimate the public health and economic burden in Mexico that would have been avoided, over the last 6 influenza seasons (from 2010-2011 to 2015-2016), if QIV had been used instead of TIV. METHODS: A static model published by Reed et al. in 2012 estimating the public health impact of QIV compared to TIV over 10 seasons in the United States was adapted to Mexico for the influenza seasons from 2010-2011 to 2015-2016. B-lineage cross-protection was included as well as public health and economic impact based on published sources. Data was obtained from inpatients and outpatients of the Mexico Emerging Infectious Diseases Clinical Research Network cohort study. The analysis was stratified by age (6-59 months, 5-17 years, 18-49 years, 50-59 years, 60 years and older) to account for heterogeneity of data, and focused on vaccination recommendations. RESULTS: During those 6 seasons, QIV would have additionally averted more than 321,000 influenza cases, 121,000 GP consultations, 3,800 hospitalisations and 330 deaths compared to TIV in this population (societal perspective cost reduction near to 13 million euros). Most benefits would have been observed for the 6-59 months group (44% of all cases avoided societal cost offsets of more than 4.6 million euros) and the elderly (32% of hospitalisation and 90% of death avoided). In adults 18-59 years, loss avoid was estimated in 1.2 million euros. CONCLUSIONS: The introduction of QIV instead of TIV would prevent a significant amount of influenza-related burden in years with high B circulation and mismatch like 2015-2016 in Mexico. However, more robust local data are needed to estimate accurately the impact of QIV. Herd effect and co-morbidities were not taken into account that could underestimate the potential impact of QIV in the recommended population.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PIN34
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)
